Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.